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Aim: To describe the speciﬁc characteristics of duodenal/perivaterian carcinoids and to analyze the
diagnostic/therapeutic approach.
Material and methods: Eight patients were included in our study. Symptoms on admission included
dyspepsia, upper gastrointestinal (GI) bleeding and anemia. All patients underwent upper GI endoscopy
and gastrointestinal peptides (gastrin) and neuroendocrine markers (Chromogranin-A, CgA) measure-
ment. Imaging studies were performed in all patients, including OCTREOSCAN, while in patients with ACs
MRCP or ERCP was also performed, when necessary. Deﬁnite diagnosis was conﬁrmed by histopathologic
examination.
Results: Polypoid masses (carcinoids) were revealed at duodenal bulb and ampulla of Vater, in 5 and 3
patients, respectively. Serum gastrin was moderately increased in 4 patients, while in one patient it was
more than 1000 pg/ml. Serum CgA was moderately increased in one patient, in whom OCTREOSCAN
detected a solitary hepatic metastasis. Two patients with DC, of less than 1 cm of diameter, were treated
by endoscopic polypectomy, while all the other patients underwent surgery. The patient with hepatic
metastasis and positive OCTREOSCAN received also Octreotide LAR, resulting in stabilization of disease.
No recurrence or metastases were observed during follow-up (range : 1.5e9.6 years).
Conclusions: In DC tumors <1 cm endoscopic excision with close follow-up is an adequate treatment,
while in tumors >1 cm and in AC, surgical resection is the treatment of choice. In metastatic tumors,
resection of the primary lesion with administration of somatostatin analogues may stabilize the disease
and improve patient’s quality of life.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Carcinoids are rare, slow growing malignancies, predominantly
arising from the Gastrointestinal (GI) tract. They are originated from
a variety of different neuroendocrine cell types and are usually
identiﬁed histologically by their afﬁnity for silver salts and by
positive reactions to neuroendocrine markers like neuron-speciﬁc
enolase (NSE), synaptophysin and chromogranin. Appendix and the
small bowel are the most frequent locations of carcinoid tumors
within the GI tract, while carcinoids of the duodenum (DC) andulla of vater carcinoids; US,
doscopic ultrasonography.
thens, Greece. Tel./fax: þ30
Nikou).
ciates Ltd. Published by Elsevier Ltespecially of the ampulla of Vater (AC) are rare tumors, accounting
for less than 2% and 0.3% of all gastrointestinal carcinoids, respec-
tively.1,2 According to the traditional classiﬁcation, proposed by
Williams et al.,3 DC andACbelong to foregut cacinoids togetherwith
thoseof the respiratory tract, stomachandpancreas.However, anew
classiﬁcation, which takes into account not only their embryological
origin, but also histologic variations of carcinoids, has recently been
adopted by many authors.4 According to this new classiﬁcation
system, neuroendocrine tumors of the duodenum and uppermost
jejunum (including those of the ampullary region) are classiﬁed as
well-differentiated endocrine tumors, well-differentiated endo-
crine carcinomas and poorly differentiated endocrine carcinomas.
In this paper, we present our experience with 8 patients with
carcinoids located in the duodenum (n ¼ 5) and the ampulla of
Vater (n ¼ 3). Clinical and pathologic features of these two rare
entities are compared and our diagnostic and therapeutic approach
is analyzed. The relevant literature is brieﬂy reviewed.d. All rights reserved.
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Amonga total numberof114patientswithcarcinoid tumorsofall origins, including
103 patients with carcinoids of the GI tract/pancreas (Table 1), we present 8 cases in
which carcinoids were located in the duodenum (n ¼ 5) and the ampulla of Vater
(n ¼ 3). These patients had been treated in the Section of Neuroendocrinology, First
Department of Propaedeutic Internal Medicine of Athens University Medical School,
“Laiko” Hospital, Athens Greece, during the last 10 years. Five patients were females,
aged from 36 to 67 years (median, 51 years) and threewere males, aged from 62 to 77
years (median, 68.3 years). The diagnosis was based upon histopathological features
and immunohistochemicalmarkers, after biopsies taken duringupperGI endoscopy or
Endoscopic Retrograde Chollangio-Pancreatography (ERCP). The following immuno-
histochemicalmarkerswere used : NSE (DakoM0873, dilution 1:50), Chromogranin-A
(Dako A 0430, dilution 1:100) and Synaptophysin (Dako M0776, dilution 1:10).
After conﬁrmation of diagnosis and endoscopic or surgical treatment, all
patients were evaluated several times per year with clinical, biochemical and
radiographic assessments. The follow-up protocol included:
1) Measurement of 24 h secretion of urinary 5-hydroxy-indole-acetic acid
(5-HIAA), and serum Chromogranin-A (CgA), every three months.
2) Measurement of serum neurohormonal peptides such as gastrin, somatostatin
and pancreatic polypeptide (PP), when necessary.
3) Liver biochemistry tests every six months and in patients with hepatic
metastases every four months.
4) Abdominal ultrasonography (US) every six months or every four months in
patients with metastases and also endoscopic ultrasonography (EUS), when
necessary.
5) Abdominal Computed Tomography (CT) scan once a year in all patients, and
Magnetic Resonance Imaging (MRI) or Magnetic Resonance Chollangio-Pan-
creatography (MRCP), when necessary.
6) Somatostatin-Receptor-Scinitigraphy (OCTREOSCAN), once a year in all
patients.
7) Upper GI endoscopy, once a year in all patients.
The follow-up period ranged between 1.5 years and 9.6 years (mean, 4.2 years) and it
is still in progress.
3. Results
3.1. Clinical features
ThreeoutofﬁvepatientswithDCwere females and2weremales,
while 2 patients with AC were females and 1 was male. Four (4/5,
80%) of the patients with DC were referred to us, because of ulcer-
like symptoms,while the other patientwas admitted to our hospital
for upper GI bleeding. On the contrary, one patient with AC pre-
sented with weakness and shortness of breath during the last 8
months due to a severe anemia (hematocrit, 18%), one patient
referred to us because of painless jaundice of 4 weeks duration,
while the other patient was admitted for malaena and painless
jaundice of sudden onset. The latter patient had also a history of von
Recklinghausen’s disease. There were no clinical signs of “carcinoid
syndrome” in any of the previous patients. The clinical features of all
patients at the time of presentation, are summarized in Table 2.
3.2. Laboratory ﬁndings
On admission, one patient with DC and two patients with AC
had anemia. Liver function tests were normal in all patients withTable 1
Carcinoid tumors of the GI tract, treated in the section of neuroendocrinology,
“Laikon” Hospital.
Tumor Location No of Patients %
Stomach 16 15.5
Duodenum and Ampulla of Vater 8 7.8
Pancreas 4 3.9
Small Intestine 31 30
Appendix 34 33
Colon and Rectum 10 9.8
Total 103 100DC, while in all patients with AC, gGT and alkaline phosphatase
(ALP) were signiﬁcantly elevated. Also, in the two patients with AC
who presented with jaundice, a mild elevation of the amino-
tranferases (AST, ALT) and increased serum bilirubin levels (up to
8.5 mg/dl) were found. Serum amylase and clotting parameters
were normal in all patients.
Serum gastrin levels were signiﬁcantly elevated in one patient
(>1000 ng/L, normal values < 108 ng/L) and slightly increased in
three patients (range, 158e395 ng/L, mean, 273 ng/L) with DC,
while it was within normal limits in all patients with AC. Serum PP
was moderately elevated (135 pmol/L, normal values : <100 pmol/
L) in the patient with high values of serum gastrin, while it was
normal in all the other patients. Serum somatostatin levels were
normal in all patients. Serum and urine neuroendocrine markers
were measured; serum CgA was found moderately increased in
seven patients (mean, 266 ng/ml) and signiﬁcantly elevated
(>800 ng/ml) in one patient with DC. In this last patient, urinary
5-HIAA was found increased (19 mg%, normal values < 9 mg%)
while the imaging studies revealed a solitary hepatic metastasis.
Urinary 5-HIAA was normal in all the other patients (Table 3).
3.3. Endoscopic e imaging ﬁndings
On upper GI endoscopy, solitary polypoid lessions (up to 1 cm in
3 patients, 1.5 cm in one patient andmore than 2 cm in one patient)
were found in the bulb of the duodenum in patients with DC
(Fig. 1). On the contrary, in one patient with AC an ulcerated,
bleeding tumor with a diameter of 4 cm was revealed in the
ampulla of Vater (Fig. 2), while in the remaining 2 patients with AC,
the endoscopy raised the suspicion of a submosal tumor of the
ampullary region. In these two patients, upper abdominal US
demonstrated a dilatation of the extrahepatic and intrahepatic bile
ducts, while in all the other patients US was without pathological
ﬁndings. The biliary ductal dilatation in the previous two patients
was conﬁrmed by the abdominal CT scan or theMRCP (Fig. 3). These
two patients underwent an ERCP, which revealed tumors of the
ampulla of Vater (Fig. 4).
Based on the histological conﬁrmation of the diagnosis, all the
previous patients underwent a Somatostatin-Receptor-Scintig-
raphy, which showed no abnormalities in seven patients, while in
the remaining patient with DC, a solitary hepatic metastasis was
revealed (Fig. 5). Of note, in this patient, CT scan and US, performed
at the same time, were without pathological ﬁndings.
3.4. Treatment
3.4.1. Endoscopic e surgical treatment
Endoscopic (snare) polypectomy was performed in 2 patients,
who had polypoid lesions in the bulb < 1 cm. In these patients the
inﬁltration of the regional lymph nodes was excluded by endo-
scopic ultrasonography (EUS), performed prior to polypectomy. In 2
patients with DC of diameter of 1.5 cm and 2.4 cm, respectively, as
well as in the patient with a DC and diameter of the mass w1 cm,
who had already a hepatic metastasis, surgical local excision with
regional lymph-node dissection was performed. Liver meta-
stasectomy was not possible due to tumor location at the conﬂu-
ence of the hepatic veins/inferior vena cava.
On the contrary, in all three patients with AC a pancreatico-
duodenectomy (Whipple procedure) with regional lymph-node
resection was performed. During the operation, in the womanwith
AC and von Recklinghausen’s disease, a second mass, of hard
consistency, measuring 3.5  3.5 cm was found in the jejunum,
approximately 15 cm distal to the ligament of Treitz, whichwas also
resected. Postoperative course was uneventful in all patients,
without any signiﬁcant postoperative complication.
Table 2
Clinical features of patients at the time of presentation.
Patient Sex - Age Tumor Upper GI Bleeding Ulcer-Like Symptoms Anemia Jaundice Von Recklinhausen
1 F 42 DC  þ   
2 F 49 DC þ  þ  
3 F 67 DC  þ   
4 M 66 DC  þ   
5 M 77 DC  þ   
6 M 62 AC    þ 
7 F 51 AC   þ  
8 F 36 AC þ  þ þ þ
DC: Duodenal carcinoids, AC: Ampullary carcinoids, PTS: Patients, GI: Gastrointestinal.
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In the patient with DC, who had already hepatic metastasis at
the time of diagnosis and positive OCTREOSCAN a long-acting
somatostatin analogue was administered (Octreotide LAR [Long-
Acting-Release, NOVARTISR], 30 mg intramuscularly, every 28 days,
initiated just after surgical resection of the primary lesion). This
patient is still treated with somatostatin analogues (3.2 years, after
surgery). No adverse effects have been reported.
3.5. Pathologic ﬁndings
Size of DC and AC ranged from 0.6 to 2.4 cm, and from 1.0 to
4.0 cm in greatest dimension, respectively. Regional lymph-node
metastases were found in the patient with metastatic DC, and in
two patients with AC. Microscopically, all tumors, either DC or AC,
were composed of medium size cells with eosinophilic cytoplasm
and central round nuclei with mild nuclear atypia. Involvement of
muscularis propria was apparent in two cases of AC. These tumors
showed a small number of mitoses (1e2 per 10 HPF) The AC of the
patient with von Recklinghausen’s disease contained psammoma
bodies. At immunohistochemistry, all DC and AC tumors expressed
chromogranin, while 4/5 of DC and 2/3 of AC expressed NSE and
synaptophysin. Four out of 5, DC tumors were positive for gastrin,
while only the AC tumor of the patient with von Recklinghausen’s
disease expressed somatostatin.
Finally, it should be pointed out that the second tumor of the
patient with von Recklinghausen’s disease was a Gastrointestinal
Stromal Tumor (GIST), showing strong immunoreactivity for S-100Table 3
Laboratory ﬁndings of patients in our series.
PT Tumor Hct% Biochemical tests Gastrin (pg/ml) Soma
1 DC 36 Normal 158 Norm
2 DC 25 Normal 1095 Norm
3 DC 39 Normal 266 Norm
4 DC 42 Normal 395 Norm
5 DC 40 Normal 65 Norm
6 AC 45 TBIL ¼ 7.2 mg/dL
AST ¼ 75 IU/L
ALT ¼ 89 IU/L
gGT ¼ 456 IU/L
ALP ¼ 853 IU/L
Normal Norm
7 AC 18 TBIL ¼ Normal
AST ¼ Normal
ALT ¼ Normal
gGT ¼ 389
ALP ¼ 658 IU/L
Normal Norm
8 AC 36 TBIL ¼ 8.5 mg/dL
AST ¼ 62 IU/L
ALT ¼ 94 IU/L
gGT ¼ 368 IU/L
ALP ¼ 693 IU/L
Normal Norm
Hct: Hematocrit, TBIL: Total Bilirubin, AST: Aspartate aminotranferase, ALT: Alanine ami
PP: Pancreatic polypeptide, CgA: Chromogranin-A, 5-HIAA: 5-Hydroxy-indole-acetic aciprotein and CD 34 and weak immunoreactivity for smooth muscle
actin. According to the new classiﬁcation of neuroendocrine tumors
of duodenum and upper jejunum, tumors of 4 patients with DC and
of 1 patient with AC were well-differentiated endocrine tumors,
while 2 patients and 1 patient with AC and DC, respectively had
well-differentiated endocrine carcinomas. Pathological ﬁndings
and immunohistochemical features of our patients are summarized
in Table 4.
3.6. Follow-up
Follow-up data are available in all patients. The follow-up period
ranged between 1.5 and 9.6 years. One patient with AC died 5.3
years after diagnosis, however his death was not attributable to the
neoplasm. All the other patients, even the patient with the meta-
static carcinoid are still alive. All patients remained asymptomatic.
Liver biochemistry tests in patients with AC returned to normal
after surgical treatment and remained within normal limits. Serum
gastrin and PP in one patient with DC decreased signiﬁcantly
(<300 pg/ml and <108 pmol/L, respectively) after endoscopic
treatment. However, serum gastrin remained moderately increased
(200e300 pg/m) during the follow-up period. Serum CgA
decreased signiﬁcantly in the patient with hepatic metastasis, after
surgical treatment and administration of somatostatin analogues,
but never returned to normal limits. On the contrary, urinary
5-HIAA levels at the same patient were normalized two months
after the initiation of medical treatment. Serum CgA, which was
moderately raised in all the other patients at the time of diagnosis,tostatin PP (pmol/L) Serum CgA (ng/ml) Urinary 5-HIAA (mg%)
al Normal 256 Normal
al 135 481 Normal
al Normal 858 19
al Normal 163 Normal
al Normal 245 Normal
al Normal 195 Normal
al Normal 204 Normal
al Normal 320 Normal
notranferase, gGT: g-glutamyl transpeptidase, ALP: Alkaline phosphatase,
d.
Fig. 1. Upper GI endoscopy, showing a carcinoid in the bulb of the duodenum.
Fig. 3. MRCP of a patient with an ampullary carcinoid, showing biliary ductal
dilatation.
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surgical treatment. Except from the patient with the DC who had
already hepatic metastasis at the time of diagnosis, no metastases
occurred in any of the other patients during the follow-up period.
Also, a stabilization of the metastatic lesion was demonstrated by
OCTREOSCAN, in the patient with the metastatic tumor, during the
follow-up period. The selected treatment and the follow-up of our
patients is summarized in Table 5.4. Discussion
Carcinoid tumors of the duodenum and especially those located
at the ampulla of Vater are rare clinical entities. Stamm et al.5
identiﬁed ﬁve major types of duodenal neuroendocrine tumors.
Gastrin-producing tumors (Type I) are the most frequent and areFig. 2. Endoscopy, revealing an ampullary carcinoid (4 cm diameter) [vertical arrow].
The horizontal arrow shows the ampulla of Vater.located predominantly in the proximal duodenum. In one third of
the patients these tumors are associated with ZollingereEllison
syndrome and Multiple Endocrine Neoplasia type I (MEN-I).
Somatostatin-producing tumors (Type II) are second in frequency,
occur preferentially at the ampulla of Vater and are often associated
with von Recklinghausen’s disease. Gangliocytic paragangliomas
(Type III) are usually located at the ampulla of Vater or in the
periampullary region. Type IV is rare and contains tumors that
produce serotonin, calcitonin and PP. These lesions are found
outside the ampulla and lack signs and symptoms of inﬁltrative
growth. Poorly differentiated endocrine carcinomas (Type V) are
extremely rare and highly malignant neoplasms, usually located at
the ampulla of Vater. The patients of our series with DC had Type I
tumors, while all of our patients with AC had Type II tumors.
Abdominal pain is thought to be the predominant symptom in
tumors located in the bulb of the duodenum, while painless jaun-
dice is the leading symptom in tumors of the ampullary region,
occurring in approximately two-thirds of patients. It has been
reported that 25% of patients with AC had a history of von Reck-
linghausen’s disease.6e8 One out of three (33%) of our patients with
AC had a similar history. Perrone9 suggested that neurogenic and
carcinoid tumors in patients with neuroﬁbromatosis occur as
a result of transformation of an endodermaleectodermal complex,
which is near the ampulla of Vater. Hough et al.10 have proposed
that patients with von Recklinghausen’s disease and abdominal
pain or jaundice should be evaluated for the possibility of anFig. 4. ERCP revealing an ampullary carcinoid after sphincterotomy.
Fig. 5. Posterior view of an OCTREOSCAN, revealing a solitary hepatic metastasis in
a patient with duodenal carcinoid.
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patient with the solitary hepatic metastasis, complained of the
typical symptoms of carcinoid syndrome (ﬂushing, diarrhea,
bronchospasm).
Upper GI endoscopy is thought to be the most useful method for
the pre-operative diagnosis of these tumors. In most cases of
polypoid lesions located in the duodenal bulb endoscopic biopsy
reveals the presence of a carcinoid tumor. On the contrary, AC are
usually located in the submucosa, the duodenal mucosa is intact,
and endoscopic biopsies are negative. In these cases, as occurred in
two of our patients, deeper biopsies after papillotomy during ERCP,
are necessary to achieve histologic diagnosis preoperatively.
Serum and urine neuroendocrine markers (such as CgA and
5-HIAA) may have diagnostic value.11e13 CgA may also have prog-
nostic signiﬁcance and can be used during the follow-up of patients.
In our series, CgA was moderately increased in seven patients and
signiﬁcantly raised in the patient with metastatic tumor, at the time
of their presentation. Urinary 5-HIAA, a serotonin metabolite, is
usually elevated in metastatic carcinoid tumors14 especially when
they are located in the small intestine and proximal colon. In our
study, it was increased only in the patient with themetastatic tumor,
while it was within normal limits in all the other patients.
A large variety of carcinoid tumors and their metastases can
express a high density of speciﬁc somatostatin receptors, particu-
larly of the subtypes 2 and 5 for which octreotide, a somatostatin
analogue, has a high afﬁnity.15 Thus, these lesions, can be visualized
in vivo using gamma camera pictures obtained after injection of
111In labeled Octreotide [(111In-DTPA0-D-Phe1)octreotide-111In-
penreotide, OCTREOSCANR]. The efﬁcacy of OCTREOSCAN, not only
to detect but also to predict a therapeutic effect of somatostatin
analogues in these tumors, has been shown by several groups.16 In
our series, OCTREOSCAN revealed an unexpected metastasis in oneTable 4
Pathologic ﬁndings and immunohistochemical features in our series.
Patient Tumor Tumor Size Classiﬁcation
1 DC 0.6 cm Well-differentiated endocrine tumor
2 DC 0.8 cm Well-differentiated endocrine tumor
3 DC 1.0 cm Well-differentiated endocrine carcinom
4 DC 2.4 cm Well-differentiated endocrine tumor
5 DC 1.5 cm Well-differentiated endocrine tumor
6 AC 1.0 cm Well-differentiated endocrine carcinom
7 AC 4.0 cm Well-differentiated endocrine tumor
8 AC 1.2 cm Well-differentiated endocrine carcinom
NSE: Neuronal speciﬁc enolase, CgA: Chromogranin-A.patient with DC, which was previously unrecognized by other
conventional imaging methods. (US, CT, MRI).
Carcinoid tumors of the duodenum can show immunohisto-
chemical evidence of multiple hormone production, while in many
cases these hormones like gastrin, pancreatic polypeptide or
somatostatin can be detected in the serum.17,18 However, only
gastrin secretion is clinically signiﬁcant in a small proportion of
patients who have ZollingereEllison syndrome.19 In larger series
with DC, only 5% of patients had documented ZollingereEllison
syndrome, although 56% secreted gastrin in serum. In our series,
gastrinwas expressed in 80% of patients with DC and serum gastrin
was elevated in all these patients, while it was normal in all three
patients with AC. Futhermore, in one of these patients gastrin levels
were more than 1000 pg/ml. However, this patient had no clinical
or other evidence of ZollingereEllison syndrome. On the other
hand, several studies have shown that more than 50% of AC tumors
express somatostatin, which may be explained by the fact that
somatostatin-producing cells have been identiﬁed in ampullary
ducts.20 In our study, only one patient with AC expressed somato-
statin, while serum somatostatin levels were normal in this patient,
as well as in all the other patients with AC.
The optimal treatment for these tumors is radical excision either
endoscopically or surgically. In small polypoid lesions (smaller than
1 cm) located in the bulb of the duodenum, an endoscopic poly-
pectomy could be an efﬁcient therapeutic approach. Local lymph-
nodemetastases should be excluded before therapeutic intervention
by endoscopic ultrasonography (EUS). Careful endoscopic follow-up
is necessary to exclude local recurrence of the tumor. Two of our
patients underwent endoscopic polypectomy. Neither local recur-
rence nor distal metastases were detected in these patients, during
the follow-up period. The remaining three patients with DC under-
went local excisionwith lymphnodedissection, as the tumor sizewas
greater than 1 cm. Surgical excision of the primary lesion was per-
formed even in the patientwho had already hepaticmetastasis at the
time of presentation, in order to reduce the intensity of his symptoms
and stabilize the disease. The latter was also achieved in the same
patient (3.2 years after the initiation of treatment), by the adminis-
tration of Somatostatin analogues (Octreotide LAR 30mg IMevery 28
days), as an additional treatment. Somatostatin analogues are
nowadays the treatment of choice in metastatic carcinoid tumors,
where they can achieve not only control of symptoms, but also
stabilizationof thedisease andeven tumor shrinkage in somecases.21
The treatment of ampullary carcinoid tumors remains contro-
versial. Although most authors agree that surgery is the treatment
of choice, the optimal operation for these tumors is under debate.
Wide local excision with lymph-node dissection has been sug-
gested for tumors smaller than 2 cm, as there seems to be no
difference in prognosis compared with a more radical procedure.22
However, regional lymph node involvement has been reported in
53% of patients with tumors smaller than 2 cm23 In our series,
lymph node involvement has been found in two patients with
tumor size of 1 and 1.2 cm, respectively.23 Furthermore, metastasesCgA NSE Synaptophysin Gastrin Somatostatin
D  D  
D D  D 
a D D D  
D D D  
D D D D 
a D D   
D  D  
a D D D  D
Table 5
Treatment and follow-up in our series.
Patient Tumor Treatment Metastases/local recurrence Serum Peptides Neuroendocrine Markers Present Status
of PTS
Duration of
Follow-up (years)
1 DC Endoscopic polypectomy e N N ANED 9.6
2 DC Endoscopic polypectomy e Gastrin: 200e300,
PP: 100e110
N ANED 4.6
3 DC Surgical local excision
þ Octreotide LAR
Stabilization of hepatic
metastasis
N Serum CgA: 300e400,
Urine 5-HIAA: N
AWD 3.2
4 DC Surgical local excision e N N ANED 1.5
5 DC Surgical local excision e N N ANED 3.2
6 AC Pancreatico-duodenectomy e N N DNED 5.3
7 AC Pancreatico-duodenectomy e N N ANED 3.5
8 AC Pancreatico-duodenectomy e N N ANED 3.1
ANED: Alive no evidence of disease, AWD: Alive with disease, DNED : Died no evidence of disease.
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tumors.24 Therefore, a more radical surgical approach, like pan-
creaticoduodenectomy (Whipple operation) appears to be more
appropriate treatment for the ampullary carcinoids, irrespective of
tumor size.25,26 Preferentially, this procedure should be performed
by experienced pancreatic surgeons, in specialized centres All of
our patients with AC underwent a Whipple’s operation. Two of
them are alive with no evidence of disease, 3.5 and 3.1 years after
surgery, while the other patient died 4.3 years after the operation
due to a myocardial infarction. It should be noted that all the
tumors of this study were well-differentiated and this may explain
at least in part the relatively good long-term outcome. Therapeutic
results could be worse for poor-differentiated tumors.
Burke et al.27 have shown that, tumor size greater than 2 cm,
inﬁltration of the muscularis propria and mitotic activity are
signiﬁcant risk factors for metastases in DC. However, one of our
patients with tumor size of approximately 1 cm had already distal
metastases at the time of diagnosis. For AC tumors, most authors
have found that tumor size has no prognostic implication, while
mitotic activity may predict outcome.28 One of our patients with
tumor size of 4 cm and lowmitotic activity is still alive without any
evidence of disease, 3.5 years after a Whipple’s operation.
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